Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease

Shima Tajahmadi; Hossein Molavi; Farhad Ahmadijokani; Amir Shamloo; Akbar Shojaei; Mohammad Sharifzadeh; Mashallah Rezakazemi; Ali Fatehizadeh; Tejraj M Aminabhavi; Mohammad Arjmand

doi:10.1016/j.jconrel.2022.11.002

Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease

J Control Release. 2023 Jan:353:1-29. doi: 10.1016/j.jconrel.2022.11.002. Epub 2022 Nov 21.

Authors

Affiliations

¹ Institute for Nanoscience and Nanotechnology (INST), Sharif University of Technology, Tehran, Iran.
² Department of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran, Iran; Department of Chemistry, Institute for Advanced Studies in Basic Science (IASBS), Gava Zang, Zanjan 45137-66731, Iran.
³ Nanomaterials and Polymer Nanocomposites Laboratory, School of Engineering, University of British Columbia, Kelowna, British Columbia V1V 1V7, Canada.
⁴ Institute for Nanoscience and Nanotechnology (INST), Sharif University of Technology, Tehran, Iran; Department of Mechanical Engineering, Sharif University of Technology, Azadi Ave., Tehran, Iran; Stem Cell and Regenerative Medicine Institute, Sharif University of Technology, Tehran 11155-9161, Iran. Electronic address: shamloo@sharif.edu.
⁵ Institute for Nanoscience and Nanotechnology (INST), Sharif University of Technology, Tehran, Iran; Department of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran, Iran.
⁶ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
⁷ Faculty of Chemical and Materials Engineering, Shahrood University of Technology, Shahrood, Iran.
⁸ Department of Environmental Health Engineering, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran; Environment Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
⁹ School of Advanced Sciences, KLE Technological University, Hubballi, Karnataka 580 031, India; School of Engineering, UPES, Bidholi, Dehradun, Uttarakhand 248 007, India. Electronic address: aminabhavit@gmail.com.
¹⁰ Nanomaterials and Polymer Nanocomposites Laboratory, School of Engineering, University of British Columbia, Kelowna, British Columbia V1V 1V7, Canada. Electronic address: mohammad.arjmand@ubc.ca.

PMID: 36343762
DOI: 10.1016/j.jconrel.2022.11.002

Abstract

Beta-amyloid (Aβ) peptide is one of the main characteristic biomarkers of Alzheimer's disease (AD). Previous clinical investigations have proposed that unusual concentrations of this biomarker in cerebrospinal fluid, blood, and brain tissue are closely associated with the AD progression. Therefore, the critical point of early diagnosis, prevention, and treatment of AD is to monitor the levels of Aβ. In view of the potential of metal-organic frameworks (MOFs) for diagnosing and treating the AD, much attention has been focused in recent years. This review discusses the latest advances in the applications of MOFs for the early diagnosis of AD via fluorescence and electrochemiluminescence (ECL) detection of AD biomarkers, fluorescence detection of the main metal ions in the brain (Zn²⁺, Cu²⁺, Mn²⁺, Fe³⁺, and Al³⁺) in addition to magnetic resonance imaging (MRI) of the Aβ plaques. The current challenges and future strategies for translating the in vitro applications of MOFs into in vivo diagnosis of the AD are discussed.

Keywords: Alzheimer's disease; Beta-amyloid; Diagnosis; MOFs; Treatment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / diagnostic imaging
Alzheimer Disease* / drug therapy
Amyloid beta-Peptides
Biomarkers
Humans
Metal-Organic Frameworks*

Substances

Metal-Organic Frameworks
Amyloid beta-Peptides
Biomarkers